With regard to adjunctive therapies, the use of lomitapide (an MTP inhibitor) or evinacumab (an ANGPTL3 inhibitor) was considered for eligible patients with refractory hypercholesterolemia. The gene discussed is ANGPTL3; the disease is Hypercholesterolemia.